Riociguat Manufacturer 625115-55-1 For Anti-hypertension CAS NO.625115-55-1

Min.Order Quantity:: 10 Gram

Purity:: 99%

Port:: Wuhan

Payment Terms:: T/T,MoneyGram

Add to Inquiry Cart

Product Details

Keywords

99%min Riociguat
Riociguat Manufacturer
For Anti-hypertension

Quick Details

ProName: Riociguat Manufacturer 625115-55-1 For...
CasNo: 625115-55-1
Molecular Formula: C20H19FN8O2
Appearance: White Powder
Application: It Can Be Used As Pharmaceutical Inte...
DeliveryTime: 2-4 days after confirming your payment...
PackAge: 100g/ bag, 2 kg/ bag, 25kg/ carton or ...
Port: Wuhan
ProductionCapacity: 10000 Metric Ton/Month
Purity: 99%
Storage: Store in sealed containers at cool & d...
Transportation: By DHL, TNT, FedEx, HKEMS, UPS, Etc
LimitNum: 10 Gram

Superiority

advantages:

hubei xinrunde chemical co., ltd is a renowned pharmaceutical manufacturer. we can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. never stop striving to offer our best service is our philosophy. we have flexible and untraceable payment terms. as a leading manufacture, our products have been exported to germany, norway, poland, finland, spain, uk, france, russia, usa, brazil, mexico, australia, japan, korea, thailand, indonesia, uruguay and many other countries.

1. quality.every batch of steroid powders have tobetested by our qc(quality control) before they are allowed to sell.

2. delivery we have stock, so we can delivery quickly at the very day when receive the payment. within 24 hours after receiving the payment lead time 4 or 7 days.

3. discreet package safelyand professionally disguised package guaranteed. for your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate.

4. warm after-sale service any of your question would be solved for the first as soon as possible.

Details

riociguat basic information

pharmacological effects clinical evaluation production method patent cases

product name:	riociguat
synonyms:	riociguat;n-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1h-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-n-methylcarbamic acid methyl ester;bay 63-2521;carbamic acid, (4,6-diamino-2-(1-((2-fluorophenyl)methyl)-1h-pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl)methyl-, methyl ester;riociguat (bay 63-2521);bay63-2521,riociguat;[4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]methylcarbamic acid methyl ester;methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate
cas:	625115-55-1
mf:	c20h19fn8o2
mw:	422.4156632
einecs:	1308068-626-2
product categories:	api
mol file:	625115-55-1.mol

riociguat chemical properties

density

1.51

riociguat usage and synthesis

pharmacological effects

riociguat is a soluble guanylyl cyclase activator, developed by the german bayer ,it is an important signaling enzyme, which can be activated by nitric oxide (no) to catalyze guanosine triphosphate ( gtp) to convert into the second messenger cyclic guanosine monophosphate (cgmp). soluble guanylate cyclase is currently the only known no receptor. damage of no-sgc-cgmp signal pathway is believed to be the cause of the incidence of cardiovascular, lung, endothelium, kidney and liver diseases. no synthesis in patients with pulmonary hypertension is not enough, no donor drugs, although effective, short half-life, riociguat can directly activate sgc, stable no-sgc combination so as to upregulate the second messenger cgmp. riociquat can significantly increase exercise tolerance in patients with hemodynamic parameters of cardiac function and prolong the time to reach clinical worsening (patent study), it may also be effective in treating cteph(chest study) .
october 8, 2013, the us fda approved riociguat for the treatment of chronic thromboembolic pulmonary hypertension and pah (pulmonary arterial hypertension).
at present, riociguat is not yet sold in the domestic market ,in the united states it is sold by the haoeyou pharmacy , the pharmacy is subsidiary of california healthcom group, because the market ofriociguat is in its infancy, its sales grow slowly.

clinical evaluation

in clinical trials ,261 patients with chronic thromboembolic pulmonary hypertension (cteph) were divided into riociguat and placebo groups, a six-minute walk distance (6mwd) as the main clinical endpoint, after 16 weeks of treatment, 6mwd of riociguat group increased by 46 meters higher than the average in the placebo group. 443 cases of pah were divided into riociguat and placebo groups,after 12 weeks of treatment, riociguat group increased 36 meters higher than the average 6mwd in the placebo group. boxed warning suggests that the drug has a embryo toxicity, pregnant patients are forbidden.
adempas is granted baseing on two global iii studies chest-1 and patent-1, whose findings are published in the july 25, 2013"new england journal of medicine," (2013; 369: 330-40; 2013; 369: 319-29). thomson reuters released analysis report that it is expected that sales of the drug in 2017 will reach $ 679 million, while the market will face a potential threat constituted by the swiss company actelion bosentan and gilead drug imber bosentan tablets.
the above information is edited by the chemicalbook of tian ye.

Post a RFQ

Cas No.:

Product Name:

Quantity: